Program
DAY1Wednesday, November 13
Please click each presentation title to see the abstract.
- Opening Remarks & Lectures
- Chair: Nagahiro Minato, Kyoto University
- 9:00-9:05
- Opening remarks
Tasuku Honjo (CCII, Kyoto University)
- 9:05-9:50
Plenary
- Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy
Suzanne Louise Topalian (Johns Hopkins University School of Medicine)
- 9:50-10:05
- On the biochemical dialog between immune cells mediating anti-cancer responses
Sidonia Fagarasan (CCII, Kyoto University)
- Session 1: T Cell Therapy
- Chair: Hiroyoshi Nishikawa, CCII, Kyoto University
- 10:05-10:45
- CAR T cells for cancer and beyond
Carl June (University of Pennsylvania)
- 10:45-11:25
- T cells naturally designed and selected to sense and eliminate cancer cells
Hilde Cheroutre (La Jolla Institute for Immunology)
- 11:25-11:40
- Break
- Session 2: Myeloid Cells, PD-1 and Beyond
- Chair: Osamu Takeuchi, Kyoto University
- 11:40-12:20
- Induction and therapeutic exploitation of PD-1 tolerogenic function
Vassiliki Boussiotis (Harvard Medical School)
- 12:20-13:00
- Liquid biopsy: from discovery to clinical implementation
Klaus Pantel (University Medical Center Hamburg-Eppendorf)
- 13:00-14:00
- Break
- Session 3: Immunometabolism
- Chair: Sidonia Fagarasan, CCII, Kyoto University
- 14:00-14:40
- High dimensional dissection and therapeutic engineering of the tumor immune microenvironment
Drew M. Pardoll (Johns Hopkins University School of Medicine)
- 14:40-15:00
Short talk
- Novel immune evasion mechanisms involving mitochondria in the tumor microenvironment
Yosuke Togashi (Okayama University)
- 15:00-15:20
Short talk
- Volatile oxidized lipids as noninvasive biomarkers for monitoring ferroptosis in cells, animal models, and human breath
Yuki Sugiura (CCII, Kyoto University)
- 15:20-15:35
- Break
- Session 4: Cancer Antigens and Tolerance
- Chair: Hideki Ueno, Kyoto University
- 15:35-16:15
- Molecular base of tumor neoantigens: intracellular expression of non-self MHC class I- and II-restricted chimeric epitopes reverses resistance to cancer immunotherapy
Kenji Chamoto (CCII, Kyoto University)
- 16:15-16:55
- Single-cell Treg profiling: new cancer therapies and insights into tumor-Treg biology
Eliane Piaggio (Curie Institute)
- 16:55-17:35
- Cancer-mediated immunosuppression in the tumor microenvironment identified by immuno-genomic analyses
Hiroyoshi Nishikawa (CCII, Kyoto University)
NEW
- 17:40-18:20
- Meet the Editors Session
- Students and early career researchers are encouraged to participate in “Meet the Editors” session and discuss with the editors of the first class papers.
- Editors: Alexandra Flemming, Chief editor, Nature Reviews Immunology
Bernd Pulverer, Chief editor, EMBO Reports